Sources of glycemic variability - What type of technology is needed?

Journal of Diabetes Science and Technology

Volumn 3, Issue 4, 2009, Pages 986-991

  Kildegaard, Jonas ^a   Christensen, Toke Folke ^b   Hejlesen, Ole Kristian ^b  

^a Kildegaard Consult   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

Author keywords

Diabetes; Glucose prediction; Insulin; Variability

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

AMBULATORY MONITORING; ARTICLE; BLOOD GLUCOSE MONITORING; EATING; GLUCOSE BLOOD LEVEL; HUMAN; INSTRUMENTATION; INSULIN INFUSION; METABOLISM;

BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; EATING; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; MONITORING, AMBULATORY;

EID: 77953049249     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680900300448     Document Type: Note

References (41)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-86.
3. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9(3):290-9.
4. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care. 1998;21(11):1910-4.
5. Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6):1614-20.
6. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care. 1981;4(3):366-76.
7. Chen JW, Christiansen JS, Lauritzen T. Limitations to subcutaneous insulin administration in type 1 diabetes. Diabetes Obes Metab. 2003;5(4):223-33.
8. Keith K, Nicholson D, Rogers D. Accuracy and precision of low-dose insulin administration using syringes, pen injectors, and a pump. Clin Pediatr (Phila). 2004;43(1):69-74.
9. Lteif AN, Schwenk WF. Accuracy of pen injectors versus insulin syringes in children with type 1 diabetes. Diabetes Care. 1999;22(1):137-40.
10. Asakura T, Seino H, Kageyama M, Yohkoh N. Dosing accuracy of two insulin pre-filled pens. Curr Med Res Opin. 2008;24(5):1429-34.
11. Bode BW, Tamborlane WV, Davidson PC. Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetes. Postgrad Med. 2002;111(5):69-77.
12. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4(5):673-82.
13. Stewart NL, Darlow BA. Insulin loss at the injection site in children with type 1 diabetes mellitus. Diabet Med. 1994;11(8):802-5.
14. Vaag A, Handberg A, Lauritzen M, Henriksen JE, Pedersen KD, Beck-Nielsen H. Variation in absorption of NPH insulin due to intramuscular injection. Diabetes Care. 1990;13(1):74-6.
15. Swan KL, Dziura JD, Steil GM, Voskanyan GR, Sikes KA, Steffen AT, Martin ML, Tamborlane WV, Weinzimer SA. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy. Diabetes Care. 2009;32(2):240-4.
16. Bergman RN, Finegood DT, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev. 1985;6(1):45-86.
17. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4(5):673-82.
18. Steil GM, Murray J, Bergman RN, Buchanan TA. Repeatability of insulin sensitivity and glucose effectiveness from the minimal model. Implications for study design. Diabetes. 1994;43(11):1365-71.
19. Spyer G, Hattersley AT, MacDonald IA, Amiel S, MacLeod KM. Hypoglycaemic counter-regulation at normal blood glucose concentrations in patients with well controlled type-2 diabetes. Lancet. 2000;356(9246):1970-4.
20. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002;45(7):937-48.
21. Karpe F, Fielding BA, Ilic V, MacDonald IA, Summers LK, Frayn KN. Impaired postprandial adipose tissue blood flow response is related to aspects of insulin sensitivity. Diabetes. 2002;51(8):2467-73.
22. Alto WA, Meyer D, Schneid J, Bryson P, Kindig J. Assuring the accuracy of home glucose monitoring. J Am Board Fam Pract. 2002;15(1):1-6.
23. Guelfi KJ, Jones TW, Fournier PA. The decline in blood glucose levels is less with intermittent high-intensity compared with moderate exercise in individuals with type 1 diabetes. Diabetes Care. 2005;28(6):1289-94.
24. Bolli GB, Gerich JE. The "dawn phenomenon" - a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med. 1984;310(12):746-50.
25. Valdes CT, Elkind-Hirsch KE. Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. J Clin Endocrinol Metab. 1991;72(3):642-6.
26. Van Cauter E, Polonsky KS, Scheen AJ. Roles of circadian rhythmicity and sleep in human glucose regulation. Endocr Rev. 1997;18(5):716-38.
27. Kildegaard J, Randløv J, Poulsen JU, Hejlesen OK. Non-model related variations profoundly impact blood glucose prediction. Proceedings of the Sixth Annual Diabetes Technology Meeting. Atlanta, GA. November 2-4, 2006.
28. Graff MR, Gross TM, Juth SE, Charlson J. How well are individuals on intensive insulin therapy counting carbohydrates? Diabetes Res Clin Pract. 2000 Suppl 1;50:238-9.
29. Mohammed NH, Wolever TM. Effect of carbohydrate source on post-prandial blood glucose in subjects with type 1 diabetes treated with insulin lispro. Diabetes Res Clin Pract. 2004;65(1):29-35.
30. Burdick J, Chase HP, Slover RH, Knievel K, Scrimgeour L, Maniatis AK, Klingensmith GJ. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics. 2004;113(3 Pt 1):e221-4.
31. Olinder AL, Kernell A, Smide B. Missed bolus doses: devastating for metabolic control in CSII-treated adolescents with type 1 diabetes. Pediatr Diabetes. 2009;10(2):142-8.
32. Alemazade R, Goldberg T, Fort P, Recker B, Lifshitz F. Reported dietary intakes of patients with insulin-dependent diabetes mellitus: limitations of dietary recall. Nutrition. 1992;8(2):87-93.
33. Kalergis M, Nadeau J, Pacaud D, Yared Z, Yale JF. Accuracy and reliability of reporting self-monitoring of blood glucose results in adults with type 1 and type 2 diabetes. Canadian J Diabetes. 2006;30(3):241-47.
34. Schütt M, Kern W, Krause U, Busch P, Dapp A, Grziwotz R, Mayer I, Rosenbauer J, Wagner C, Zimmermann A, Kerner W, Holl RW, DPV Initiative. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria. Exp Clin Endocrinol Diabetes. 2006;114(7):384-8.
35. Chen ET, Nichols JH, Duh SH, Hortin G. Performance evaluation of blood glucose monitoring devices. Diabetes Technol Ther. 2003;5(5):749-68.
36. Skeie S, Thue G, Nerhus K, Sandberg S. Instruments for self-monitoring of blood glucose: comparisons of testing quality achieved by patients and a technician. Clin Chem. 2002;48(7):994-1003.
37. Kovachev B, Anderson S, Heinemann L, Clarke W. Comparison of the numerical and clinical accuracy of four continuous glucose monitors. Diabetes Care. 2008;31(6):1160-4.
38. International Organization for Standardization. In vitro diagnostic test systems: requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus (ISO 15197).Geneva: International Organization for Standardization; 2003.
39. Bode B, Silver M, Weiss R, Martin K. Evaluation of a continuous glucose monitoring system for home-use conditions. Manag Care. 2008;17(8):40-5.
40. Buckingham B, Cobry E, Clinton P, Gage V, Caswell K, Kunselman E, Cameron F, Chase HP. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technol Ther. 2009;11(2):93-7.
41. Gross TM, Kayne D, King A, Rother C, Juth S. A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. Diabetes Technol Ther. 2003;5(3):365-9.